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Specific biomarkers for C9orf72 FTD/ALS
could expedite the journey towards
effective therapies
Rubika Balendra1,2, Thomas G Moens1,2 & Adrian M Isaacs1
A hexanucleotide repeat expansion in the
C9orf72 gene is a common genetic cause
of ALS and FTD. The repeats are translated
into five different dipeptide repeat
proteins (DPRs). In this issue, Lehmer et al
(2017) demonstrate that one of these
DPRs, poly(GP), can be measured in the
CSF of individuals with C9orf72 mutations.
In conjunction with the findings from
another recent study (Gendron et al,
2017), these DPR biomarkers may prove to
be extremely valuable in the quest for
effective therapies for C9FTD/ALS.
See also: C Lehmer et al and TF Gendron
et al
T he discovery that GGGGCC expan-sions in the C9orf72 gene are themost common genetic cause of amyo-
trophic lateral sclerosis (ALS) and fron-
totemporal dementia (FTD), collectively
termed C9FTD/ALS, has transformed our
understanding of these diseases (Rohrer
et al, 2015). Proposed pathogenic mecha-
nisms include loss of function of C9orf72
protein, and two gain-of-function mecha-
nisms: toxicity from C9orf72 repeat RNA or
from DPRs produced by repeat-associated
non-ATG translation, of which there are
five, poly(GA), poly(GP), poly(GR), poly
(PR) and poly(PA). There has been rapid
translation of our understanding of the
disease towards developing new therapies,
especially for antisense oligonucleotides
(ASOs), with human trials planned shortly.
ASOs target C9orf72 repeat RNA and can
mitigate several C9orf72 repeat-induced
pathologies both in vitro and in vivo (Zhang
et al, 2015; Jiang et al, 2016; Gendron et al,
2017).
Although there is great excitement at the
prospect of imminent clinical trials, it is criti-
cal we apply the lessons from past failures.
In ALS, despite numerous Phase II/III clini-
cal trials of potential therapeutics, only one
drug, riluzole, has been shown to have a
minimal effect on prolonging survival.
The reasons for this are multifactorial
(Mitsumoto et al, 2014), but one key factor
that will facilitate better studies is demon-
strating that biological effects are dependent
on target engagement in appropriate and
robust preclinical models and in subsequent
clinical trials. This could be achieved by
incorporating validated pharmacodynamic
biomarkers, which demonstrate a biological
effect in response to a therapeutic interven-
tion, into preclinical and human studies.
Importantly, an international effort to
update the Guidelines for Clinical Trials in
ALS to reflect these concepts is currently
underway, with publication of the recom-
mendations expected shortly.
Two key studies, one presented in this
issue (Lehmer et al, 2017) and another
recent study (Gendron et al, 2017), offer the
tantalising prospect of such a biomarker for
C9FTD/ALS. Building upon a previous study
in a smaller cohort (Su et al, 2014), they
validate that CSF poly(GP) is a sensitive and
specific biomarker of C9orf72 expansions
using Meso Scale Discovery immunoassays,
in both asymptomatic and symptomatic
individuals.
In cellular and animal models, poly(GR)
and poly(PR) are the most toxic DPRs, with
poly(GA) also leading to some toxicity.
However, both studies chose to measure
poly(GP) for several reasons: (i) poly(GP) is
one of the most frequent DPRs in C9FTD/
ALS central nervous system (CNS) tissue;
(ii) it is more soluble than poly(GA), which
is the most frequent DPR; (iii) it appears to
be a highly stable DPR, as demonstrated by
its persistence in cultured iPSC-derived
neurons (Gendron et al, 2017); and (iv) it is
produced from both sense and antisense
C9orf72 transcripts, although it is worth
noting that ASO studies suggest sense tran-
scripts are the major origin.
Interestingly, both studies show that CSF
poly(GP) levels are comparable in asymp-
tomatic and symptomatic individuals,
although Gendron et al (2017) find a non-
significant trend towards an increase in
symptomatic individuals. Further large-scale,
longitudinal studies will help determine if
levels increase with symptom onset. Detec-
tion of poly(GP) in asymptomatic mutation
carriers is in line with pathology studies
showing CNS DPR inclusions can be present
prior to symptom onset, and suggests that
poly(GP) is being released from living
neurons, rather than those undergoing
neurodegeneration. Neither study finds an
increase in CSF poly(GP) with disease
progression, either measured longitudinally,
or using clinical scores such as the
revised ALS Functional Rating Scale and
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FTLD-specific Clinical Dementia Rating, or
an association with an ALS or FTD pheno-
type, age of disease onset, or survival. This
stability of poly(GP) levels may enhance its
value as a pharmacodynamic biomarker. In a
clinical trial, for each patient, relative pre-
and post-intervention values would be
compared; therefore, a stable marker show-
ing normalisation with a therapy is ideal. As
an elegant proof of principle of this concept,
Gendron et al (2017) show that treating
C9orf72 iPSC-derived neurons and a C9orf72
mouse model with ASOs reduces poly(GP)
levels. The levels of intracellular poly(GP) in
C9orf72 iPSC neurons correlates with extra-
cellular levels in media bathing the cells, and
in a mouse model, CSF poly(GP) correlates
with poly(GP) in brain homogenates. This
indicates that CSF poly(GP) levels are likely
to reflect intraneuronal levels in the CNS.
However, it is important to note that in their
longitudinal analysis of a small patient
cohort, in some individuals CSF poly(GP)
naturally decreases over time, which should
be accounted for in clinical trials. An emerg-
ing theme from trials in Alzheimer’s disease
(AD) is that administering treatment early
in the disease course, before extensive
neurodegeneration, may be most effective;
therefore, detection of CSF poly(GP) in
asymptomatic individuals may have great
value for implementing early treatment.
Lehmer et al (2017) show that CSF levels of
neurofilaments (Nfl and pNfH), markers of
axonal damage, are raised in symptomatic
but not asymptomatic C9orf72 mutation
carriers, in agreement with recent studies of
neurofilaments as ALS diagnostic and prog-
nostic biomarkers (Fig 1). The combination
of both biomarkers could provide evidence
of target engagement and functional rescue.
Lehmer et al (2017) suggest CSF poly
(GP) could be used alongside genotyping as
a diagnostic biomarker, and were able to
reclassify one patient misdiagnosed with
AD as C9FTD. Due to somatic instability of
GGGGCC repeats, it is possible that patients
without an expansion in blood DNA have
expansions in the CNS; therefore, the addi-
tion of CSF poly(GP) could add diagnostic
value. However, it is important to note that
both studies describe a small number of
false positives, non-C9orf72 individuals with
elevated poly(GP), or false negatives,
C9orf72 individuals with non-detectable
poly(GP). Improving the sensitivity and
specificity of these assays is critical and
may require the use of other potentially
more sensitive platforms, such as the Simoa
(single molecule array), which was used on
a subset of samples by Gendron et al
(2017). Lehmer et al (2017) use monoclonal
antibodies in their immunoassay, which are
less variable and can be produced at higher
throughput than polyclonal antibodies, so
may provide an additional advantage.
Developing similar assays for other more
toxic DPRs may also be beneficial, as they
may correlate better with progression or
prognosis.
In addition to CSF, Gendron et al (2017)
specifically detected poly(GP) in peripheral
blood mononuclear cells. Detection in blood
would be advantageous for repeat measure-
ments in clinical trials. This could mark a
significant step forward, but further studies
are needed to determine whether blood and
CSF poly(GP) levels correlate.
In conclusion, developing promising
biomarkers should be integral to clinical
trials in C9FTD/ALS, and a biomarker
assay should ideally be sensitive, specific,
reproducible with low variability, standard-
ised and affordable. These studies now
highlight CSF poly(GP) as one such poten-
tial candidate.
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Figure 1. C9FTD/ALS CSF biomarkers.
CSF poly(GP) is similar in asymptomatic and symptomatic individuals, whilst CSF neurofilaments are detected in symptomatic individuals.
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